• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Verastem Inc (NQ: VSTM )

    2.940 -0.160 (-5.16%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 563,950
    Open 3.130
    Bid (Size) 2.940 (1)
    Ask (Size) 2.990 (5)
    Prev. Close 3.100
    Today's Range 2.935 - 3.130
    52wk Range 2.935 - 14.22
    Shares Outstanding 25,325,551
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    VERASTEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Verastem, Inc. on Behalf of Verastem Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)
    From Kirby McInerney LLP
    Via Business Wire

    Performance

    YTD
    -64.58%
    -64.58%
    1 Month
    -26.87%
    -26.87%
    3 Month
    -74.63%
    -74.63%
    6 Month
    -63.43%
    -63.43%
    1 Year
    -65.61%
    -65.61%

    More News

    Read More
    7 F-Rated Stocks to Avoid at All Costs in June
    Via InvestorPlace
    VSTM Stock Earnings: Verastem Beats EPS for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Crude Oil Rises 1%; Verastem Shares Slide
    Via Benzinga
    Exposures Fossil Fuels
    Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Nasdaq Gains 1%; Intuit Shares Plunge
    Via Benzinga
    Is the Stock Market Open on Memorial Day 2024?
    Via InvestorPlace
    7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split
    Via InvestorPlace
    NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial
    Via InvestorPlace
    Topics Intellectual Property
    Exposures Intellectual Property
    Why Is Verastem (VSTM) Stock Down 62% Today?
    Via InvestorPlace
    Dow Surges 50 Points; US Durable Goods Orders Increase In April
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
    Via Benzinga
    Exposures Product Safety
    Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Verastem Oncology
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.